Development and Validation of a Vascular Endothelial Growth Factor A-associated Prognostic Model for Unresectable Hepatocellular Carcinoma

References

• Sung H, Ferlay J, Siegel RL., et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Llovet JM, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19(3):151–172. doi:10.1038/s41571-021-00573-2
   PubMed Web of Science ®Google Scholar
• Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604. doi:10.1038/s41575-019-0186-y
   PubMed Web of Science ®Google Scholar
• Kloeckner R, Galle PR, Bruix J. Local and regional therapies for hepatocellular carcinoma. Hepatology. 2021;73(Suppl S1):137–149. doi:10.1002/hep.31424
   PubMedGoogle Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314. doi:10.1016/s0140-6736(18)30010-2
   PubMed Web of Science ®Google Scholar
• Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150(4):835–853. doi:10.1053/j.gastro.2015.12.041
   PubMed Web of Science ®Google Scholar
• Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol. 2010;7(8):209–249. doi:10.3322/caac.21660
   Web of Science ®Google Scholar
• Sangro B, Salem R. Transarterial chemoembolization and radioembolization. Semin Liver Dis. 2014;34(4):435–443. doi:10.1055/s-0034-1394142
   PubMed Web of Science ®Google Scholar
• Rou WS, Lee BS, Moon HS, Lee ES, Kim SH, Lee HY. Risk factors and therapeutic results of early local recurrence after transcatheter arterial chemoembolization. World j Gastroenterol. 2014;20(22):6995–7004. doi:10.3748/wjg.v20.i22.6995
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390. doi:10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34. doi:10.1016/s1470-2045(08)
   PubMed Web of Science ®Google Scholar
• Zhu YJ, Zheng B, Wang HY, Chen L. New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol Sin. 2017;38(5):614–622. doi:10.1038/aps.2017.5
   PubMed Web of Science ®Google Scholar
• Rizzo A, Nannini M, Novelli M, Dalia Ricci A, Scioscio VD, Pantaleo MA. Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis. Ther Adv Med Oncol. 2020;12:1758835920936932. doi:10.1177/1758835920936932
   Web of Science ®Google Scholar
• Chao Y, Wu C-Y, Kuo C-Y, et al. Cytokines are associated with postembolization fever and survival in hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization. Hepatol Int. 2013;7(3):883–892. doi:10.1007/s12072-012-9409-9
   PubMed Web of Science ®Google Scholar
• Chan SL, Yeo W, Mo F, et al. A Phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma. Cancer. 2017;123(20):3977–3985. doi:10.1002/cncr.30825
   PubMed Web of Science ®Google Scholar
• Kaseb AO, Hassan MM, Lin E, et al. V-CLIP: integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials. Cancer. 2011;117(11):2478–2488. doi:10.1002/cncr.25791
   PubMed Web of Science ®Google Scholar
• Cai R, Song R, Pang P, et al. Transcatheter arterial chemoembolization plus sorafenib versus transcatheter arterial chemoembolization alone to treat advanced hepatocellular carcinoma: a meta-analysis. BMC Cancer. 2017;17(1):714. doi:10.1186/s12885-017-3707-5
   PubMedGoogle Scholar
• Zhang X, Wang K, Wang M, et al. Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis. Oncotarget. 2017;8(17):29416–29427. doi:10.18632/oncotarget.15075
   PubMedGoogle Scholar
• Geschwind J-F, Kudo M, Marrero JA, et al. TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: final Analysis of GIDEON. Radiology. 2016;279(2):630–640. doi:10.1148/radiol.2015150667
   PubMed Web of Science ®Google Scholar
• Li J, Zhang F, Yang J, et al. Combination of individualized local control and target-specific agent to improve unresectable liver cancer managements: a matched case-control study. Target Oncol. 2015;10(2):287–295. doi:10.1007/s11523-014-0338-5
   PubMed Web of Science ®Google Scholar
• Zhu K, Chen J, Lai L, et al. Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: treatment with Transarterial Chemoembolization Combined with Sorafenib—A Retrospective Controlled Study. Radiology. 2014;272(1):284–293. doi:10.1148/radiol.14131946
   PubMed Web of Science ®Google Scholar
• Li L, Zhao W, Wang M, et al. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis. BMC Gastroenterol. 2018;18(1):138. doi:10.1186/s12876-018-0849-0
   PubMed Web of Science ®Google Scholar
• Kudo M, Ueshima K, Ikeda M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2020;69(8):1492–1501. doi:10.1136/gutjnl-2019-318934
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM, Han G, et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. J Hepatol. 2016;64(5):1090–1098. doi:10.1016/j.jhep.2016.01.012
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Gadaleta-Caldarola G, Brandi G. First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges. Expert Rev Gastroenterol Hepatol. 2021;15(11):1245–1251. doi:10.1080/17474124.2021.1973431
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Di Federico A, et al. Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: where Do We Stand? Front Oncol. 2021;11:803133. doi:10.3389/fonc.2021.803133
   PubMed Web of Science ®Google Scholar
• Bolondi L, Burroughs A, Dufour J-F, et al. Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis. 2012;32(4):348–359. doi:10.1055/s-0032-1329906
   PubMed Web of Science ®Google Scholar
• Kadalayil L, Benini R, Pallan L, et al. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol. 2013;24(10):2565–2570. doi:10.1093/annonc/mdt247
   PubMed Web of Science ®Google Scholar
• Yamakado K, Miyayama S, Hirota S, et al. Subgrouping of intermediate-stage (BCLC stage B) hepatocellular carcinoma based on tumor number and size and Child–Pugh grade correlated with prognosis after transarterial chemoembolization. Jpn J Radiol. 2014;32(5):260–265. doi:10.1007/s11604-014-0298-9
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60. doi:10.1055/s-0030-1247132
   PubMed Web of Science ®Google Scholar
• Rodriguez-Canales J, Parra-Cuentas E, Wistuba II. Diagnosis and Molecular Classification of Lung Cancer. Cancer Treat Res. 2016;170:25–46. doi:10.1007/978-3-319-40389-2_2
   PubMedGoogle Scholar
• Hothorn T, Zeileis A. Generalized maximally selected statistics. Biometrics. 2008;64(4):1263–1269. doi:10.1111/j.1541-0420.2008.00995.x
   PubMed Web of Science ®Google Scholar
• de Sousa VML, Carvalho L. Heterogeneity in Lung Cancer. Pathobiology. 2018;85(1–2):96–107. doi:10.1159/000487440
   PubMed Web of Science ®Google Scholar
• Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–7259. doi:10.1158/1078-0432.Ccr-04-0713
   PubMed Web of Science ®Google Scholar
• Komoll R-M, Hu Q, Olarewaju O, et al. MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma. J Hepatol. 2021;74(1):122–134. doi:10.1016/j.jhep.2020.07.039
   PubMed Web of Science ®Google Scholar
• Fu Z, Li X, Zhong J, et al. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study. Hepatol Int. 2021;15(3):663–675. doi:10.1007/s12072-021-10184-9
   PubMed Web of Science ®Google Scholar
• Xie D-Y, Ren Z-G, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020;9(4):452–463. doi:10.21037/hbsn-20-480
   PubMed Web of Science ®Google Scholar
• Pinter M, Hucke F, Graziadei I, et al. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiology. 2012;263(2):590–599. doi:10.1148/radiol.12111550
   PubMed Web of Science ®Google Scholar
• Chung GE, Lee J-H, Kim HY, et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology. 2011;258(2):627–634. doi:10.1148/radiol.10101058
   PubMed Web of Science ®Google Scholar
• Luo J, Guo R-P, Lai ECH, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol. 2011;18(2):413–420. doi:10.1245/s10434-010-1321-8
   PubMed Web of Science ®Google Scholar
• Kudo M, Matsui O, Izumi N, et al. JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. Liver Cancer. 2014;3(3–4):458–468. doi:10.1159/000343875
   PubMed Web of Science ®Google Scholar
• Meyer T, Fox R, Ma YT, et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, Phase 3 trial. Lancet Gastroenterol Hepatol. 2017;2(8):565–575. doi:10.1016/S2468-1253(17)30156-5
   PubMed Web of Science ®Google Scholar
• Morse MA, Sun W, Kim R, et al. The Role of Angiogenesis in Hepatocellular Carcinoma. Clin Cancer Res. 2019;25(3):912–920. doi:10.1158/1078-0432.CCR-18-1254
   PubMed Web of Science ®Google Scholar
• Lacin S, Yalcin S. The Prognostic Value of Circulating VEGF-A Level in Patients With Hepatocellular Cancer. Technol Cancer Res Treat. 2020;19:1533033820971677. doi:10.1177/1533033820971677
   Web of Science ®Google Scholar
• Jin-no K, Tanimizu M, Hyodo I, et al. Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma. J Gastroenterol. 1998;33(3):376–382. doi:10.1007/s005350050099
   PubMed Web of Science ®Google Scholar
• Godin C, Bodeau S, Saidak Z, et al. Early decrease in serum amphiregulin or vascular endothelial growth factor levels predicts sorafenib efficacy in hepatocellular carcinoma. Oncol Rep. 2019;41(3):2041–2050. doi:10.3892/or.2018.6922
   PubMed Web of Science ®Google Scholar
• Lin Z-H, Jiang J-R, Ma X-K, et al. Prognostic value of serum HIF-1α change following transarterial chemoembolization in hepatocellular carcinoma. Clin Exp Med. 2021;21(1):109–120. doi:10.1007/s10238-020-00667-8
   PubMed Web of Science ®Google Scholar
• Shim JH, Park J-W, Kim JH, et al. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Science. 2008;99(10):2037–2044. doi:10.1111/j.1349-7006.2008.00909.x
   PubMed Web of Science ®Google Scholar
• Horwitz E, Stein I, Andreozzi M, et al. Human and mouse VEGFA -amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment. Cancer Discov. 2014;4(6):730–743. doi:10.1158/2159-8290.CD-13-0782
   PubMed Web of Science ®Google Scholar
• Liu X, Lu J, Zhang G, et al. A Machine Learning approach yields a multiparameter prognostic marker in liver cancer. Cancer Immunol Res. 2021;9(3):337–347. doi:10.1158/2326-6066.CIR-20-0616
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–693. doi:10.1016/j.jhep.2021.11.018
   PubMed Web of Science ®Google Scholar
• Bruix J, Cheng A-L, Meinhardt G, Nakajima K, De Sanctis Y, Llovet J. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies. J Hepatol. 2017;67(5):999–1008. doi:10.1016/j.jhep.2017.06.026
   PubMed Web of Science ®Google Scholar
• Chou W-C, Lee C-L, Yang T-S, et al. Changes in serum α-fetoprotein level predicts treatment response and survival in hepatocellular carcinoma patients and literature review. J Formosan Med Assoc. 2018;117(2):153–163. doi:10.1016/j.jfma.2017.03.010
   PubMed Web of Science ®Google Scholar
• Carr BI, D’Alessandro R, Refolo MG, et al. Effects of low concentrations of regorafenib and sorafenib on human HCC cell AFP, migration, invasion, and growth in vitro. J Cell Physiol. 2013;228(6):1344–1350. doi:10.1002/jcp.24291
   PubMed Web of Science ®Google Scholar
• Chen T, Dai X, Dai J, et al. AFP promotes HCC progression by suppressing the HuR-mediated Fas/FADD apoptotic pathway. Cell Death Dis. 2020;11(10):822. doi:10.1038/s41419-020-03030-7
   PubMed Web of Science ®Google Scholar
• Schobert IT, Savic LJ, Chapiro J, et al. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE. Eur Radiol. 2020;30(10):5663–5673. doi:10.1007/s00330-020-06931-5
   PubMed Web of Science ®Google Scholar
• Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med. 2000;342(17):1266–1271. doi:10.1056/NEJM200004273421707
   PubMed Web of Science ®Google Scholar
• Yu M-C, Chan K-M, Lee C-F, et al. Alkaline phosphatase: does it have a role in predicting hepatocellular carcinoma recurrence? J Gastrointest Surg. 2011;15(8):1440–1449. doi:10.1007/s11605-011-1537-3
   PubMed Web of Science ®Google Scholar
• Zhu Y, Xu D, Zhang Z, et al. A new laboratory-based algorithm to predict microvascular invasion and survival in patients with hepatocellular carcinoma. Int J Surg. 2018;57:45–53. doi:10.1016/j.ijsu.2018.07.011
   PubMed Web of Science ®Google Scholar
• Sun P, Chen S, Li Y. The association between pretreatment serum alkaline phosphatase and prognosis in hepatocellular carcinoma: a meta-analysis. Medicine. 2020;99(11):e19438. doi:10.1097/MD.0000000000019438
   PubMed Web of Science ®Google Scholar
• Chen C, Qiu H, Yao Y, et al. Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients. Clin Res Hepatol Gastroenterol. 2021;45(2):101460. doi:10.1016/j.clinre.2020.05.008
   PubMed Web of Science ®Google Scholar
• Jia F, Wu B, Yan R, Li L, Wang K, Han D. Prediction Model for Intermediate-Stage Hepatocellular Carcinoma Response to Transarterial Chemoembolization. J Magn Reson Imaging. 2020;52(6):1657–1667. doi:10.1002/jmri.27189
   PubMed Web of Science ®Google Scholar
• Chen R-X, Gan Y-H, Ge N-L, et al. A new prediction model for prognosis of patients with intermediate-stage HCC after conventional transarterial chemoembolization: an internally validated study. J Cancer. 2019;10(26):6535–6542. doi:10.7150/jca.34064
   PubMed Web of Science ®Google Scholar
• Wang Q, Xia D, Bai W, et al. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: a multicentre observational study. J Hepatol. 2019;70(5):893–903. doi:10.1016/j.jhep.2019.01.013
   PubMed Web of Science ®Google Scholar
• Chu HH, Chun S-Y, Kim JH, et al. A prediction model for overall survival after transarterial chemoembolization for hepatocellular carcinoma invading the hepatic vein or inferior vena cava. Eur Radiol. 2021;31(6):4232–4242. doi:10.1007/s00330-020-07536-8
   PubMed Web of Science ®Google Scholar
• Li J-R, Wu M-J, Wang T, et al. A prognostic score model for predicting the survival benefits of patients undergoing sorafenib plus transarterial chemoembolization for hepatocellular carcinoma with portal vein invasion. Abdom Radiol. 2021;46(5):1967–1976. doi:10.1007/s00261-020-02897-6
   PubMed Web of Science ®Google Scholar
• Fako V, Martin SP, Pomyen Y, et al. Gene signature predictive of hepatocellular carcinoma patient response to transarterial chemoembolization. Int J Biol Sci. 2019;15(12):2654–2663. doi:10.7150/ijbs.39534
   PubMed Web of Science ®Google Scholar
• Tang Y, Wu Y, Xue M, Zhu B, Fan W, Li J. A 10-Gene Signature Identified by Machine Learning for Predicting the Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. J Oncol. 2022;2022:3822773. doi:10.1155/2022/3822773
   PubMed Web of Science ®Google Scholar
• Di Federico A, Rizzo A, Carloni R, et al. Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials. Expert Opin Investig Drugs. 2022;31(4):361–369. doi:10.1080/13543784.2022.2009455
   PubMed Web of Science ®Google Scholar
• Xia S, Pan Y, Liang Y, Xu J, Cai X. The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma. EBioMedicine. 2020;51:102610. doi:10.1016/j.ebiom.2019.102610
   PubMed Web of Science ®Google Scholar
• He Q, Yang J, Jin Y. Development and Validation of TACE Refractoriness-Related Diagnostic and Prognostic Scores and Characterization of Tumor Microenvironment Infiltration in Hepatocellular Carcinoma. Front Immunol. 2022;13:869993. doi:10.3389/fimmu.2022.869993
   PubMed Web of Science ®Google Scholar
• Ren Z, Yue Y, Zhang Y, et al. Changes in the Peripheral Blood Treg Cell Proportion in Hepatocellular Carcinoma Patients After Transarterial Chemoembolization With Microparticles. Front Immunol. 2021;12:624789. doi:10.3389/fimmu.2021.624789
   PubMed Web of Science ®Google Scholar
• Loosen SH, Schulze-Hagen M, Leyh C, et al. IL-6 and IL-8 Serum Levels Predict Tumor Response and Overall Survival after TACE for Primary and Secondary Hepatic Malignancies. Int J Mol Sci. 2018;19(6):Jun. doi:10.3390/ijms19061766
   Web of Science ®Google Scholar
• Fujiwara N, Friedman SL, Goossens N, Hoshida Y. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol. 2018;68(3):526–549. doi:10.1016/j.jhep.2017.09.016
   PubMed Web of Science ®Google Scholar